Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Clinica San Camilo, Argentina
- Target Recruit Count
- 200
- Registration Number
- NCT04530578
- Locations
- 🇦🇷
Clinica San Camilo, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Massimo Girardis
- Target Recruit Count
- 210
- Registration Number
- NCT04528888
- Locations
- 🇮🇹
ICU- University Hospital Modena, Modena, Italy
FREEDOM COVID-19 Anticoagulation Strategy
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Valentin Fuster
- Target Recruit Count
- 3460
- Registration Number
- NCT04512079
- Locations
- 🇨🇴
Centro Médico Imbanaco, Cali, Colombia
🇨🇴Clínica Shaio, Bogotá, Colombia
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2020-08-11
- Target Recruit Count
- 130
- Registration Number
- NCT04508439
- Locations
- 🇲🇽
Hospital Regional de Alta Especialidad de Ixtapaluca, Mexico City, Ixtapaluca, Mexico
Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Thrombosis Research Institute
- Target Recruit Count
- 219
- Registration Number
- NCT04492254
- Locations
- 🇦🇺
Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital, Melbourne, Australia
🇧🇪Dr Frank Cools, National Co-ordinating Investigator, AZ Klina, Brasschaat, Belgium
🇿🇦Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand, Johannesburg, South Africa
Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 100
- Registration Number
- NCT04462003
- Locations
- 🇪🇬
Faculty of Medicine,Beni-Suef University, Banī Suwayf, Beni-Suef, Egypt
Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 301
- Registration Number
- NCT04427098
- Locations
- 🇮🇹
Fondazione Poliambulanza Chirurgia Vascolare, Brescia, Italy
🇮🇹Piazzale Spedali Civili, 1, 25123 Brescia BS Medicina Interna UniBS 2° Medicina ASST Spedali Civili, Brescia, Italy
🇮🇹Ospedale Morgagni Pierantoni U.O.C. Malattie Infettive, Forlì, Italy
High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Azienda Ospedaliero-Universitaria di Modena
- Target Recruit Count
- 300
- Registration Number
- NCT04408235
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria, Modena, Italy
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
- Conditions
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 14
- Registration Number
- NCT04406389
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 257
- Registration Number
- NCT04401293
- Locations
- 🇺🇸
Lenox Hill Hospital, New York, New York, United States
🇺🇸Beth Israel Newark, Newark, New Jersey, United States
🇺🇸Staten Island University Hospital, Staten Island, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.